Regeneron's Pasatru wins FDA nod as second FOP therapy, first to cut flare-ups and new bone lesions
The US Food and Drug Administration has cleared Regeneron's Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, marking the second approved treatment for this ultra-rare condition and the first to show meaningful reductions in both new heterotopic ossification lesions and clinician-assessed flare-ups. What changed for FOP patients? Fibrodysplasia ossificans progressiva is a rare genetic disease in which soft tissues such as muscle, tendon and ligament
10 hours ago3 min read
FDA Clears Ultragenyx Gene Therapy for Glycogen Storage Disease Type Ia
The U.S. Food and Drug Administration has granted accelerated approval to Genglycos, a one-time gene therapy developed by Ultragenyx Pharmaceutical for adults and children aged eight years and older with glycogen storage disease type Ia. The approval makes Genglycos the first FDA-authorized treatment for this rare inherited metabolic disorder. It is also designed to address the genetic cause of the disease rather than focusing only on managing its symptoms. What causes glycog
2 days ago3 min read
FDA Grants Accelerated Approval to Zenbexus Combination for Relapsed Multiple Myeloma | iPharmaCenter
The US Food and Drug Administration has granted accelerated approval to Zenbexus, also known as iberdomide, in combination with daratumumab and hyaluronidase plus dexamethasone for adults with multiple myeloma previously treated with at least one regimen containing both a proteasome inhibitor and an immunomodulatory medicine. The approval is based on findings from the Phase 3 EXCALIBER-RRMM study, which evaluated the Zenbexus combination in patients with relapsed or refractor
7 days ago2 min read
FDA clears Pluvicto earlier in PSMA positive metastatic prostate cancer
The U.S. Food and Drug Administration has authorized Pluvicto for use with standard hormone blocking regimens in adults with PSMA positive metastatic hormone sensitive prostate cancer. The decision allows clinicians to combine the radioligand therapy with androgen deprivation and androgen receptor pathway inhibitors in patients whose disease is still hormone sensitive, significantly increasing the group eligible for this targeted approach. PSMAddition data underpin the label
Aug 42 min read
FDA Approves Otsuka’s SIMTRIYO as First-in-Class NDSRI for ADHD
The U.S. Food and Drug Administration has granted approval to Otsuka Pharmaceutical for SIMTRIYO (centanafadine), marking the first regulatory clearance for a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) intended for the treatment of attention-deficit/hyperactivity disorder (ADHD). Indicated for pediatric patients aged 6 years and older weighing at least 20kg, as well as adult patients, the medication is formulated as a once-daily, extended-release capsule.
Jul 272 min read